STOCKS TELEGRAPH

Tag: Oncolytics Biotech Inc

  • Why Has The Oncolytics (ONCWF) Stock Price Gained 68% In Last Session?

    Why Has The Oncolytics (ONCWF) Stock Price Gained 68% In Last Session?

    The share price of Oncolytics Biotech Inc. (OTCPink: ONCWF) closed up 68.45 percent on Friday at $0.1420, with the stock trading between $0.1226 and $0.1420 during the day. The ONCWF stock has gained 74.88% over the last 12 months, reaching a high of $3.0000. The ONCWF stock rose after the company released clinical and biomarker data.

    The data referred to what?

    Biotechnology company Oncolytics develops pelareorep, an immunotherapeutic agent delivered intravenously. It enhances the inflamed phenotype of cancerous tumours, leading to the transformation of “cold” tumors into “hot” ones through innate and adaptive immunity to treat a variety of cancers.

    Pelereorep, developed by ONCWF, has demonstrated synergies with immune checkpoint inhibitors. It may also be effective with other immunotherapy agents. Last week, Oncolytics announced that preliminary trial results for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer demonstrate clinical proof-of-concept.

    A poster presentation will be presented using digital data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4 – 8, 2021. Oncwf’s new data come from a study of pembrolizumab (KEYTRUDA) in tandem with pelareorep in pancreatic adenocarcinoma patients who had not responded to first-line therapy.

    These results show that pembrolizumab and pelareorep synergize and show anticancer activity in patients who have been resistant to other therapies, and that this synergy stems from their complementary immunotherapeutic actions.

    In what ways does ONCWF expects to succeed?

    The trial results report by ONCWF are extremely encouraging, especially with the complex patient population that was enrolled in the study. Oncolytics (ONCWF) observed a response signal in select patients, despite lack of chemotherapy, which suggests pelareorep-pembrolizumab treatment combination therapy shows substantial anti-cancer activity.

  • Oncolytics Biotech Inc. (ONCY) stock Rises today: Why is it so?

    Oncolytics Biotech Inc. (ONCY) stock Rises today: Why is it so?

    Shares of Oncolytics Biotech Inc. (ONCY) were down today amid the announcement of the preclinical data on Pelareorep-based combination therapies at the annual meeting held in the American Association for Cancer Research(AACR). ONCY stock price saw a downtrend of 5.71% to drop at $3.78 a share at the time of this writing. ONCY stock was red in the last trading session and was down by 13.58% at closing. Let’s deep dive to explore more of it.

    What’s happening?

    The data presented by ONCY stock in the AACR annual meeting represents the ability of the pelareorep to synergize with multiple anti-cancer agents. poly (ADP)-ribose polymerase 1 (PARP-1) inhibitor talazoparib and the Cyclin-dependent kinase (CDK) 4/6 inhibitor Palbociclib showed the top results, and both of these were approved by the U.S.A Food and Drug Administration for the cure of breast cancer.

    The data of the study of AWARE-1 window-of-opportunity breast cancer met the trials primary endpoint according to the representation given by ONCY at the meeting. The data is represented in the electronic poster at AARC which include twenty HR+/HER2- early-stage breast cancer patients in AWARE-1’s first two cohorts. The treatment was done through pelareorep and letrozole without cohort 1 or with cohort 2 before the surgery. The main purpose of AWARE-1 is to evaluate the cohort 1 and cohort 2.

    The CEO of Oncolytics Biotech said that the current data of the clinical and preclinical study support pelareorep that has much high potential to increase the effectiveness of various immunotherapies as well as wide range of immunotherapeutic agents.

    Aleix Prat, Translational Principal Investigator of AWARE-1, said that the AWARE-1 data confirms the fact that the pelareorep interact with the checkpoint inhibitors in order to train the immune system in battle against cancer.

    About ONCY stock:

    Oncolytics Biotech Inc. (ONCY) is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to treat cancer in patients. Pelareorep is the lead product of Oncology which is used to treat solid tumors and hematological malignancies. ONCY founded in 1998 and its headquarters is in Calgary, Canada.

    Conclusion:

    Things are gloomy for ONCY stock as far as market sentiment is concerned. ONCY stock happened to be green at one point today but then again became red. Hence individuals eyeing Oncology stock need to do a lot of research before taking any decision.